RESULTS FROM A 52-WEEK, NONINTERVENTIONAL STUDY OF BRAZILIAN INDIVIDUALS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS: RATES OF BLEEDING, FVIII USE, AND QUALITY OF LIFE

RESULTS FROM A 52-WEEK, NONINTERVENTIONAL STUDY OF BRAZILIAN INDIVIDUALS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS: RATES OF BLEEDING, FVIII USE, AND QUALITY OF LIFE

Regular prophylaxis with exogenous Factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data on bleeding, FVIII use, and quality of life (QoL) for this population in routine clinical practice are scarce. In a prospective, multinational, noninterventiona...

Full description

Bibliographic Details
Main Authors:	GG Yamaguti-Hayakawa, PR Villaça, C Lorenzato, MH Cerqueira, LCO Oliveira, ACKVD Nascimento, CBF Dametto, DB Reddy, H Yu, MC Ozelo
Format:	Article
Language:	English
Published:	Elsevier 2021-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S253113792100540X

Similar Items

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
by: Gili Kenet, et al.
Published: (2021-12-01)

BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1
by: MC Ozelo, et al.
Published: (2023-10-01)

O IMPACTO DA TERAPIA GÊNICA NA SAÚDE MUSCULOESQUELÉTICA DE PACIENTES COM HEMOFILIA A GRAVE
by: GG Yamaguti-Hayakawa, et al.
Published: (2023-10-01)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
by: Cihan Ay, et al.
Published: (2021-06-01)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
by: Kenet G, et al.
Published: (2023-06-01)

Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model
by: Mario Eandi, et al.
Published: (2013-04-01)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
by: Fadzlin Mohd Mokhtar, et al.
Published: (2021-12-01)

Utilization evaluation of factor concentration and frequencyof bleeds among patients with haemophilia "A" and haemophilia "B" in northwest Iran
by: Roya Dolatkhah, et al.
Published: (2013-12-01)

Impact of novel hemophilia therapies around the world
by: Margareth C. Ozelo, et al.
Published: (2022-03-01)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
by: Maria Sol Cruz, et al.
Published: (2021-05-01)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
by: Sajjad Afraz, et al.
Published: (2022-11-01)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
by: Gili Kenet, et al.
Published: (2023-08-01)

A case of idiopathic acquired haemophilia - A with massive subcutaneous bleeding
by: Sunil Raviraj Kothakota, et al.
Published: (2021-01-01)

Determinants and modifiers of bleeding phenotypes in haemophilia-A: General and tropical perspectives
by: Umma A. Ibrahim, et al.
Published: (2018-07-01)

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII
by: Bredon Crawford, et al.
Published: (2015-01-01)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
by: Christian Lubich, et al.
Published: (2022-10-01)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
by: Michael U. Callaghan, et al.
Published: (2022-08-01)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
by: K. Huang, et al.
Published: (2022-06-01)

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients.
by: Sandra B van Os, et al.
Published: (2017-01-01)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
by: Jin Jea Sung, et al.
Published: (2019-04-01)

Haemophilia specialist nurses’ perceptions of haemophilia B
by: Chaplin Steve, et al.
Published: (2021-10-01)

ADHERENCE TO PROPHYLAXIS IN RELATION TO QUALITY OF LIFE AND ANXIETY LEVEL IN TURKISH PATIENTS WITH SEVERE HAEMOPHILIA A
by: Zuhre Kaya
Published: (2020-12-01)

CORRELATION OF THE PARAMETERS OF THROMBO-ELASTOGRAM WITH THE RESULTS OF COAGULATIOIN TESTS IN HAEMOPHILIA A PATIENTS DURING PROPHYLAXIS
by: V. V. Krasivska, et al.
Published: (2019-09-01)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals
by: S. van Os, et al.
Published: (2020-01-01)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients
by: S. van Os, et al.
Published: (2018-01-01)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
by: Cansu Hemşinlioğlu, et al.
Published: (2023-06-01)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
by: Louise H Hooimeijer MD, et al.
Published: (2023-03-01)

International consensus recommendations on the management of people with haemophilia B
by: Daniel P. Hart, et al.
Published: (2022-04-01)

The child with haemophilia
by: C. D. Karabus
Published: (1981-09-01)

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab
by: Pierre Fontana, et al.
Published: (2020-12-01)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
by: Martin Rodriguez, et al.
Published: (2023-07-01)

Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report
by: Claire Berger, et al.
Published: (2023-12-01)

In-Silico Characterization of von Willebrand Factor Bound to FVIII
by: Valentina Drago, et al.
Published: (2022-08-01)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
by: Swystun LL, et al.
Published: (2023-03-01)

How to Manage a Patient with Haemophilia and ACS Requiring PCI: A Battle between Bleeding and Thrombosis
by: Konstantinos C. Theodoropoulos, et al.
Published: (2021-04-01)

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
by: Brady Trevisan, et al.
Published: (2022-12-01)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
by: Chao Lien Liu, et al.
Published: (2016-06-01)

Arthroplasty of the elbow in haemophilia.
by: Chapman-Sheath, P, et al.
Published: (2003)